DB:ISI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. More Details


Snowflake Analysis

Excellent balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has Ionis Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ISI's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-0.09%

ISI

-5.6%

DE Biotechs

-1.8%

DE Market


1 Year Return

-20.0%

ISI

-4.2%

DE Biotechs

1.7%

DE Market

Return vs Industry: ISI underperformed the German Biotechs industry which returned 1.1% over the past year.

Return vs Market: ISI underperformed the German Market which returned 2.6% over the past year.


Shareholder returns

ISIIndustryMarket
7 Day-0.09%-5.6%-1.8%
30 Day-6.7%-14.2%-1.6%
90 Day-23.9%-14.1%-1.8%
1 Year-20.0%-20.0%-4.1%-4.2%4.9%1.7%
3 Year-15.6%-15.6%-0.7%-1.6%2.0%-6.9%
5 Year-3.1%-3.1%46.7%44.2%24.2%6.5%

Price Volatility Vs. Market

How volatile is Ionis Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Ionis Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

20.3%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ISI (€40.07) is trading below our estimate of fair value (€50.26)

Significantly Below Fair Value: ISI is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ISI is poor value based on its PE Ratio (50.9x) compared to the XE Biotechs industry average (35.3x).

PE vs Market: ISI is poor value based on its PE Ratio (50.9x) compared to the German market (22.6x).


Price to Earnings Growth Ratio

PEG Ratio: ISI is good value based on its PEG Ratio (0.8x)


Price to Book Ratio

PB vs Industry: ISI is overvalued based on its PB Ratio (4.8x) compared to the DE Biotechs industry average (4.4x).


Next Steps

Future Growth

How is Ionis Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?

65.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ISI's forecast earnings growth (65.7% per year) is above the savings rate (0.2%).

Earnings vs Market: ISI's earnings (65.7% per year) are forecast to grow faster than the German market (26.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ISI's revenue (14.5% per year) is forecast to grow faster than the German market (6.1% per year).

High Growth Revenue: ISI's revenue (14.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ISI is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Ionis Pharmaceuticals performed over the past 5 years?

61.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ISI has high quality earnings.

Growing Profit Margin: ISI's current net profit margins (13.8%) are lower than last year (50.4%).


Past Earnings Growth Analysis

Earnings Trend: ISI's earnings have grown significantly by 61.6% per year over the past 5 years.

Accelerating Growth: ISI's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: ISI had negative earnings growth (-67.7%) over the past year, making it difficult to compare to the Biotechs industry average (3.1%).


Return on Equity

High ROE: ISI's Return on Equity (7.5%) is considered low.


Next Steps

Financial Health

How is Ionis Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: ISI's short term assets ($2.5B) exceed its short term liabilities ($231.3M).

Long Term Liabilities: ISI's short term assets ($2.5B) exceed its long term liabilities ($1.3B).


Debt to Equity History and Analysis

Debt Level: ISI's debt to equity ratio (49.6%) is considered high.

Reducing Debt: ISI's debt to equity ratio has reduced from 132.1% to 49.6% over the past 5 years.

Debt Coverage: ISI's debt is well covered by operating cash flow (27%).

Interest Coverage: ISI's interest payments on its debt are well covered by EBIT (87.4x coverage).


Balance Sheet


Next Steps

Dividend

What is Ionis Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ISI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ISI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ISI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ISI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ISI's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Brett Monia (59 yo)

0.75

Tenure

US$6,527,963

Compensation

Dr. Brett P. Monia, Ph.D., is a Founder of Ionis Pharmaceuticals, Inc. and has been its Chief Executive Officer since 2020. He is President and Director of Akcea Therapeutics, Inc. since October 12, 2020. ...


CEO Compensation Analysis

Compensation vs Market: Brett's total compensation ($USD6.53M) is above average for companies of similar size in the German market ($USD3.53M).

Compensation vs Earnings: Brett's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Stanley Crooke
Founder & Executive Chairman29.67yrsUS$9.60m0.47%
$ 26.1m
Brett Monia
Founder0.75yrUS$6.53m0.021%
$ 1.2m
Elizabeth Hougen
Executive VP of Finance & CFO7.75yrsUS$3.48m0.023%
$ 1.3m
Patrick O'Neil
Executive VP of Legal7.75yrsUS$3.46m0.015%
$ 845.1k
B. Parshall
Senior Strategic Advisor & Director20.08yrsUS$2.43m0.048%
$ 2.7m
Richard Geary
Executive Vice President of Development12.17yrsUS$3.91m0.022%
$ 1.2m
Darren Gonzales
Chief Accounting Officer & Senior VP0.67yrno datano data
C. Bennett
Executive VP & Chief Scientific Officer0.75yrUS$958.87k0.023%
$ 1.3m
D. Walke
Vice President of Investor Relations8.25yrsno datano data
Roslyn Patterson
VP of Marketing & Communicationsno datano datano data
Onaiza Cadoret-Manier
Executive VP and Chief Corporate Development & Commercial Officer0.75yrno datano data
Shannon Devers
Senior Vice President of Human Resources0.67yrno datano data

1.8yrs

Average Tenure

60.5yo

Average Age

Experienced Management: ISI's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Stanley Crooke
Founder & Executive Chairman29.67yrsUS$9.60m0.47%
$ 26.1m
Brett Monia
Founder0.75yrUS$6.53m0.021%
$ 1.2m
B. Parshall
Senior Strategic Advisor & Director20.08yrsUS$2.43m0.048%
$ 2.7m
Joan Herman
Independent Director1.33yrsUS$3.23m0.0038%
$ 212.9k
Joseph Klein
Independent Director14.83yrsUS$1.17m0.012%
$ 669.5k
Joseph Wender
Independent Director26.75yrsUS$1.16m0.063%
$ 3.5m
Frederick Muto
Independent Director19.58yrsUS$1.15m0.024%
$ 1.3m
Michael Hayden
Independent Director2.08yrsUS$1.15m0.0026%
$ 142.1k
Breaux Castleman
Independent Director7.33yrsUS$1.15m0.014%
$ 765.4k
Spencer Berthelsen
Independent Director18.42yrsUS$1.16m0.072%
$ 4.0m
Joseph Loscalzo
Independent Director6.67yrsUS$1.14m0.012%
$ 690.7k
Peter Reikes
Independent Director2.08yrsUS$1.13m0.0026%
$ 142.1k

11.1yrs

Average Tenure

67.5yo

Average Age

Experienced Board: ISI's board of directors are seasoned and experienced ( 11.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Ionis Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ionis Pharmaceuticals, Inc.
  • Ticker: ISI
  • Exchange: DB
  • Founded: 1989
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$6.594b
  • Listing Market Cap: US$5.574b
  • Shares outstanding: 139.70m
  • Website: https://www.ionispharma.com

Number of Employees


Location

  • Ionis Pharmaceuticals, Inc.
  • 2855 Gazelle Court
  • Carlsbad
  • California
  • 92010
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IONSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 1991
ISIDB (Deutsche Boerse AG)YesCommon StockDEEURMay 1991
IONSSWX (SIX Swiss Exchange)YesCommon StockCHCHFMay 1991
0JDILSE (London Stock Exchange)YesCommon StockGBUSDMay 1991
IONS *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNMay 1991

Biography

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/20 20:53
End of Day Share Price2020/10/20 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.